While all recipients (10/10) given TCD-BM alone died with progressive tumor growth by 20 days after HCT, addition of STAT3–/– T cells eliminated the BCL1/Luc+ tumor cells by 10 days after HCT, and most (6/10) of the recipients survived for more than 100 days (Figure 2, A and B). The gene discussed is STAT3; the disease is neoplasm.